Latest Aethlon Medical Inc. Stories
SAN DIEGO, Jan. 17, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that Laszlo Radvanyi, Ph.D., an Associate Professor in the Department of Melanoma Medical Oncology Research at the University of Texas MD Anderson Cancer Center in Houston, has joined its Scientific Advisory Board. "I am excited to be a part of...
SAN DIEGO, Jan. 15, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) In 2012, researchers published the discovery that small particles known as exosomes are secreted by tumors to seed the creation and spread of cancer metastases. These same tumor-secreted exosomes have also been implicated in death of immune cells necessary to...
SAN DIEGO, Jan. 8, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced that Chief Executive Officer Jim Joyce will give a corporate presentation today at Biotech Showcase 2013. The presentation is scheduled to start at 4:45 p.m. Pacific Standard Time and can be accessed online at http://www.media-server.com/m/p/54bc8kj7. The conference is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel. (Photo:...
SAN DIEGO, Jan. 3, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that it has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) that requests permission to initiate a clinical feasibility study of Hepatitis-C (HCV) infected individuals enrolled to receive...
SAN DIEGO, Dec. 7, 2012 /PRNewswire/ --Aethlon Medical, Inc. (OTCBB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. At Aethlon Medical, our focus is to create revolutionary medical devices that save lives. In the treatment of Hepatitis C (HCV) infected individuals, we have demonstrated that our Hemopurifier® synergistically combines with drug therapy to accelerate the achievement of undetectable viral load. In cancer, I envision our...
SAN DIEGO, Dec. 3, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today announced the initiation of a compassionate-use clinical program to treat individuals infected with Hepatitis C virus (HCV). The compassionate-use program, which has been approved by the Institutional Review Board at the Medanta Medicity Institute (Medicity),...
SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that the European Patent Office (EPO) has provided the Company a notice of intent to issue European Patent Application No. 04 703 672.8 entitled "Method For Removal of Viruses From Blood By Lectin Affinity Hemodialysis." The patent describes a medical...
SAN DIEGO, Oct. 25, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, disclosed today that U.S. Patent number 8,288,172 was issued to the Company by the U.S. Patent and Trademark Office (USPTO) on October 16(th), 2012. The patent entitled "Extracorporeal Removal of Microvesicular Particles," provides Aethlon Medical the exclusive right...
SAN DIEGO, Oct. 9, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), announced that Chairman and CEO Jim Joyce will present at the RedChip 15(th) Annual Fall Small-Cap Conference this Thursday, October 11, 2012 at the Palace Hotel in San Francisco. A live webcast of the presentation will begin at 2:15 p.m. Pacific time (5:15 p.m. Eastern time) and can be accessed online at: http://redchip.com/visibility/conferencePages/SanFran2012/conferenceMain.asp?page=preregister...
SAN DIEGO, Oct. 3, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), today released the slide-deck underlying a presentation given yesterday by its Chairman and CEO, Jim Joyce at the EXOSOMES & MICROVESICLES 2012 conference in Orlando, Florida. The presentation was entitled: Extracorporeal clearance of tumor-secreted exosomes as an adjunct to enhance cancer therapy efficacy. (Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b) The presentation focused on...
